MENU

VYNE Stock VYNE Therapeutics (VYNE, $2.25) price may climb as it broke lower Bollinger Band on Jun 07, 2024

A.I.dvisor
at Tickeron.com
06/08/24
Loading...
VYNE - VYNE Therapeutics
Bollinger signal
Bullish Trend
Odds of UP Trend
Tickeron
Bollinger signal
Price: $2.25
Daily change: -$0.13 (-5.46%)
Daily volume: 21.4K
Capitalization: $32.7M
Industry: Biotechnology
This price move could be a signal that VYNE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 43 similar cases where VYNE's price broke its lower Bollinger Band, and of them led to a successful outcome. Odds of Success:

Aroon Indicator for VYNE shows an upward move is likely

VYNE's Aroon Indicator triggered a bullish signal on November 14, 2024. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 118 similar instances where the Aroon Indicator showed a similar pattern. In of the 118 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for VYNE moved above the 200-day moving average on November 13, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VYNE advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for VYNE moved out of overbought territory on November 11, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 43 cases where VYNE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for VYNE turned negative on November 13, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYNE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VYNE broke above its upper Bollinger Band on November 05, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VYNE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.659) is normal, around the industry mean (14.655). P/E Ratio (0.863) is within average values for comparable stocks, (96.848). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.824). VYNE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (227.273) is also within normal values, averaging (218.428).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYNE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
VYNE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in development and commercialization of serlopitant products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
685 Route 202/206 North
Phone
+1 800 775-7936
Employees
10
Web
https://www.vynetherapeutics.com